is rybelsus a glp-1 drug Pill Cut Heart Failure Events in Some Diabetes Patients Article » ProAct

The primary outcome was the new onset of adverse CVEs, including heart failure, composite incidence of major adverse cardiovascular events (MACE

New analyses involving more than 100,000 patients suggest that users of popular diabetes and weight-loss medications face a lower risk of developing certain cancers and a reduced risk of metastasis.

Improved blood sugar regulation and metabolic health

GLP-1 agonists market report provides insights for patient pool, challenges, drugs and future market trends in the 7MM

While their glycemic, weight-lowering, and cardiovascular benefits are well established through randomized trials and meta-analyses, concerns remain regarding their safety and tolerability across diverse populations and clinical settings